17/07/2026 China NMPA grants approval to iza‑bren, delivering survival benefit in recurrent/metastatic ESCC after PD‑1/PD‑L1 therapy China NMPA grants approval to iza‑bren, delivering survival benefit in recurrent/metastatic ESCC after PD‑1/PD‑L1 therapy (Ref) China’s NMPA approved Biokin Pharma's iza-bren (izalontamab brengitecan; EGFR x HER3 bispecific ADC) for recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after progression on platinum-based chemotherapy

11/05/2026 FDA grants Fast Track to Zai Lab’s DLL3‑targeting ADC Zocilurtatug Pelitecan (Zoci) for epNECs Hansoh Pharma’s HS-20093 B7-H3 ADC wins NMPA Breakthrough Therapy nod in ESCC Innovent’s IBI363 secures third Breakthrough Therapy Designation in China, advancing to Phase III for MSS/pMMR colorectal cancer with Takeda partnership FDA grants Fast Track to Zai Lab’s DLL3‑targeting ADC Zocilurtatug Pelitecan (Zoci) for epNECs (Ref) Zai Lab's : Zocilurtatug pelitecan (Zoci,